Sherene Loi

Address Peter MacCallum Cancer Centre
Melbourne
Country

Australia

Sherene Loi

Sherene Loi is a Medical Oncologist specialised in breast cancer treatment as well as clinician scientist with expertise in genomics, immunology and drug development. Her work is focused on developing new therapeutic approaches that may improve outcomes of breast cancer patients.

After completing Medical Oncology specialist clinical training in 2003 she undertook a PhD and postdoctoral studies at the Institut Jules Bordet in Brussels, Belgium (2003-2012). In 2013, she returned to head the newly created Translational Breast Cancer Genomics and Therapeutics laboratory at the Peter MacCallum Cancer Centre, Melbourne, as well as Consultant Medical Oncologist in the Breast Service and head of the Breast Cancer Clinical Trials Unit. She is recognised internationally as a leading clinician scientist whose work has led to new insights into the immunology field in breast cancer. As a result of her research, she leads a number of international breast cancer clinical trials in immunotherapy.

Over her career to date she has published over 180 peer-reviewed research articles with a lifetime H index of 57. Her recent work has been highly influential with 18,789 total citations and 13,404 (71%) within the past 5 years (Google Scholar). She is on the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (BCT Australia/NZ), which is the largest breast cancer clinical trials cooperative group in Australia. She is also co-chair of the Translational Working Group of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries world-wide. She is the current holder of the inaugural National Breast Cancer Foundation of Australia Endowed Chair. She is a research fellow of the Breast Cancer Research Foundation (BCRF), New York and she is on the Scientific Committee for Breast Cancer for the American Society of Clinical Oncology (ASCO).